CoChat

Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men

Arver, Stefan, Dobs, Adrian S., Meikle, A. Wayne, Caramelli, Kim E., Rajaram, Lakshminaryan, Sanders, Steven W., Mazer, Norman A. · 1997 · Clinical Endocrinology
Cited by 128

The DOI matches its Crossref record.

Abstract

OBJECTIVE: An important aim in treating male hypogonadism is restoration of physiological concentrations of testosterone and its metabolites. We have assessed hormone levels, pharmacokinetics and clinical response, including safety, of a permeation‐enhanced testosterone transdermal system (TTD) in the treatment of hypogonadal men for a 12‐month period. DESIGN: Open‐label, multicentre study with four consecutive periods: Period I (3 weeks)—evaluation of patients' current androgen therapy, which consisted primarily of testosterone enanthate injections (mean dose 229 mg; mean interval 26d); Period II (8 weeks)—androgen washout; Period III (3–4 weeks)—single‐dose pharmacokinetic studies of TTD systems; Period IV (12 months)—efficacy, safety, and steady‐state pharmacokinetic evaluation of TTD systems (5 mg/day nominal delivery rate of testosterone). Results from Periods I, II, and IV were compared. PATIENTS: Thirty‐seven hypogonadal men 21–65 years old enrolled; 34 entered Periods III and IV; 29 (9 primary, 20 secondary hypogonadism) completed the study. Four patients withdrew because of adverse events (Period II, one; Period IV, three). MEASUREMENTS: Morning serum levels of total testosterone (T), bioavailable testosterone (BT), dihydrotestosterone (DHT), and oestradiol (E 2) levels. Circadian pattern of T profiles and 24‐hour time‐average T level. LH levels in patients with primary hypogonadism. Reduction of hypogonadal symptoms. Safety assessments including skin tolerability, prostate parameters, lipid profile, and systemic parameters. RESULTS: Twelve months of TTD therapy normalized morning serum T levels in 93% of patients, and produced greater than 80% normalization of BT, DHT and E 2 levels. The TTD system mimicked the circadian variation in T levels seen in healthy young men and normalized 24‐hour time‐average T levels in 86% of patients. Luteinizing hormone was suppressed in 8 of 9 men with primary hypogonadism, and normalized in 5 of these. Subjective symptoms of hypogonadism, including decreased libido and fatigue, showed improvement after 2–4 weeks of TTD treatment in most patients. The majority of adverse events were local skin reactions, and 3 patients (9%) discontinued the study for this reason. Prostate assessments showed a lower prostate‐specific antigen level during TTD therapy compared to IM injections (0.66 vs 1.00 μg/l P < 0.001), while prostate size did not differ significantly between the two treatment regimens. CONCLUSIONS: The permeation‐enhanced testosterone transdermal system produces physiological levels and circadian patterns of testosterone, and its metabolites, in hypogonadal men. Although transient erythema and itching is commonly reported, the TTD is generally well tolerated by most patients. This system offers a new treatment option for testosterone replacement therapy that results in physiological serum levels of sex hormones in hypogonadal men.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.1997.3071113.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 128

Metadata

Authors
Arver, S., Dobs, A. S., Meikle, A. W., Caramelli, K. E., Rajaram, L., Sanders, S. W., & Mazer, N. A.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1997-12
Volume
47
Issue
6
Pages
727-737
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1969032321
Cited by
128
References
0
FWCI
4.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men. https://app.cochat.ai/papers/10.1046/j.1365-2265.1997.3071113.x
The paper
Arver, S., Dobs, A. S., Meikle, A. W., Caramelli, K. E., Rajaram, L., Sanders, S. W., & Mazer, N. A. (1997). Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1997.3071113.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.